Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Renalytix Ai Plc LSE:RENX London Ordinary Share GB00BYWL4Y04 ORD 0.25P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -50.00 -7.87% 585.00 570.00 600.00 630.00 582.50 630.00 65,457 11:41:25
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Pharmaceuticals & Biotechnology 0.0 -0.4 -1.0 - 348

Renalytix Ai Share Discussion Threads

Showing 601 to 623 of 625 messages
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
DateSubjectAuthorDiscuss
12/8/2020
15:27
individual US stock prices can be extremely volatile on news and on selling - just because they have so many pople / money over there. Something we'll be getting used to im sure - including more volatility on news flow - hopefully positive!
nimbo1
12/8/2020
13:50
The pullback is certainly silly, but the market makers know full well they'll get sellers or trigger stop losses, so it's any easy way to get cheap shares. NASDAQ closed at $15.68, which is equivalent to £6, so that should have been the floor really... Overshoot to the downside vs the US, undershoot on the upside - C'est la vie.
74tom
12/8/2020
13:23
Fear of losing a few quid for some plus yesterday's drop on the Nasdaq. Healthy or not I'd sooner see it going up than down.
busterdog2
12/8/2020
13:06
Not sure I understand that pull-back on such light trading.
toffeeman
12/8/2020
09:20
A healthy pull back, perhaps created by some being less-than-impressed with the Stifle initiation coverage? It's always best to be somewhat conservative, especially at this stage ;-)
wan
12/8/2020
08:57
Haha, yes AIM is the rag doll these days! Plenty of newsflow on the way to look forward to :) And thanks as always for the excellent research Wan, plenty of tailwinds to drive RENX commercially.
74tom
12/8/2020
08:41
Tracking the Nasdaq price in yesterday’s market sell off. Works both ways we can be reassured to know :)
nimbo1
11/8/2020
12:36
A relevant post from the EKF thread - The COVID/healthcare situation has, and is, resulting in rapid changes in the diagnostics and life science sector. And in my view, there is a lot of weight forming behind the dynamics now in play, both associated to and beyond COVID-19, and in which diagnostics will play an increasingly important part. In this regard, the following article provides for an informative read and a read across to EKF's (and Renalytix) relationship and agreement with Mount Sinai, which provides EKF with advanced access to data and innovative commercial opportunities arising from Mount Sinai Health System owned technologies managed by MSIP in the field of digital diagnostics. Addressing Covid-19 is a data problem – here’s how the data community is harnessing healthcare data to solve it Data can allow us to improve our public health response to the pandemic, but only if we enable data scientists with the right tools to harness those datasets. By FRANK NOTHAFT Aug 10, 2020 Hospital systems Digital transformation has been a slow burn for most hospital systems, but Covid-19 has ignited an accelerated effort, especially in the move toward analytics of consolidated health records. Hospitals use multiple different Electronic Health Record (EHR) systems that have complex data storage and analytics architectures. These complex architectures mean that these systems can’t easily interact, making it difficult to collect all the data that will provide a complete picture of a patient, which is necessary for building accurate machine learning models. Ultimately, data scientists working with legacy EHR architectures spend more time freeing data from their EHR, and less time building innovative models that can improve patient outcomes. Pharmaceutical and diagnostics companies While hospitals meet immediate healthcare needs and governments focus on controlling the spread, many pharmaceutical and diagnostics companies are focusing their energies on developing diagnostic tests, treatments, and vaccines for Covid-19. These organizations need help analyzing both clinical and real-world observational health data to determine how a drug is being used both in clinical trial settings and compassionate use to treat patients impacted by the virus. A lot of biopharma and diagnostics companies have been using data about the spread of coronavirus to adjust their clinical trials and manufacturing programs rapidly. With this data, they can make sure that medicines and tests are still getting to patients in need, and they can look at how the novel coronavirus is impacting patients in the disease areas that they are focused on. Full story - hTTps://medcitynews.com/2020/08/addressing-covid-19-is-a-data-problem-heres-how-the-data-community-is-harnessing-healthcare-data-to-solve-it/?rf=1 In short, EKF (and Renalytix) appear well placed for the accelerated revolution taking place in the integration of data and new digital health solutions.
wan
11/8/2020
10:49
Thanks Nimbo
wan
11/8/2020
10:38
Thanks HB This from Stifel note confirms commercial testing begins this month. Initiation Penetration Within Mount Sinai; Other Deals To Follow. This month, the Mount Sinai Hospital System will begin using KidneyIntelX to manage the ~65,000 patients with DKD (Stages 1-3), which should provide a strong initial test volume ramp, particularly given the population health approach being undertaken (wherein implementation will be hospital-wide). Over the next 12 months, additional patient populations within Mount Sinai will likely become eligible for testing, and we expect new accounts to be announced in the form of formal partnerships with other hospital systems and/or payor networks. We also see strong potential for pharma relationships that could yield another key revenue stream going forward.
nimbo1
11/8/2020
10:37
hTTps://twitter.com/saharainvesting/status/1293104016902283264 'Stifel (Buy, $22 PT) and JPMorgan (Neutral, $19 PT) initiate on Renalytix $RNLX #RENX this morning JPM modeling 2025 sales of $254m and 10% operating margin. Stifel are at $182m for 2025 sales, but have a 16% operating margin by 2023'
homebrewruss
11/8/2020
07:45
Most readers will be aware of the recent Mount Sinai Health System and Renalytix initiation of a multi-centre study to conduct in-depth investigations into kidney-related complications and long-term outcomes linked to COVID-19. The following transcript provides more (sobering) context - Samira S. Farouk, MD, MS Assistant Professor, Department of Medicine, Division of Nephrology, Icahn School of Medicine at Mount Sinai, New York, NY The Kidney and COVID-19: What We Know so Far Samira S. Farouk, MD, MS; Matthew Sparks, MD August 10, 2020 Sparks: How many patients in the intensive care unit (ICU) who had COVID-19 and AKI would require kidney replacement therapy? Farouk: It's hard to give a number, but it would definitely be upwards of 50%, 60%, or even 70%. As nephrology consultants, we are obviously called for the patients who require dialysis in the ICU, and at the peak there were many more patients requiring dialysis in the ICU than we had ever seen before. Summary Sparks: Great. Let me summarize what we talked about with COVID-19 and the kidneys. One, it has provided an opportunity for and also showed the importance of nephrology care during a pandemic. Two, kidney injury is common, and if that develops, especially in an ICU, the need for kidney replacement therapy is high. We as a workforce, as a group, need to understand that and have the resources available. SARS-CoV-2 could impact the kidney but it's likely a rare event. Most AKI episodes are from acute tubular necrosis, which can be from a variety of things — the illness, being sick in hospital or in the ICU, hemodynamic factors, and other things. The risk in patients on dialysis or those with transplant is definitely not lower and may be comparable to that of the general population or slightly worse. We need to stay vigilant to ensure that this vulnerable group of patients socially distance, wear a mask, and do all the things that need to be done to diminish the risk. Are Hospitals Better Prepared? Sparks: Are hospitals in the United States better prepared for kidney complications now? What are the long-term implications for individuals who have gone through COVID-19 and have experienced AKI? Farouk: Having been in a New York hospital that was in the epicenter, with a very high volume of patients requiring dialysis and kidney replacement therapies, I definitely think we are better prepared if we were to experience a second wave. In the initial few weeks as the peak was developing, we tried different tactics to make sure we were using our dialysis resources in the most effective way possible. We are well equipped to roll those out again. We put strategies in place to ensure that faculty and trainees were not assigned to too many patients. We could reinstitute those rescheduling plans. We had specific plans for our nursing staff to ensure safety as well as adequate patient care. We would likely bring back the utilization of acute peritoneal dialysis in the ICU. We have a plan written down and ready to go in the event of another surge. Obviously, we hope that does not happen. The second question, about long-term effects on patients, unfortunately is something that we do not know. I think most experts would agree that there will likely be some long-standing impact on the kidneys and this will likely become an important cause of chronic kidney disease. Many institutions, including ours, have begun to build COVID-19 follow-up care centers, not only to better understand the long-term sequelae of this disease, but also to provide care for patients who may develop long-term organ damage. I know this has also been seen in the pulmonary world with persistent pulmonary symptoms like cough or shortness of breath. I don't think the kidney is much different. We know it can be a somewhat sensitive organ. Those who had severe infection and severe AKI requiring kidney replacement therapy will likely see some long-term sequelae and perhaps, unfortunately, an increase in the prevalence of chronic kidney disease. What is important is that clinicians and researchers continue to share their data in a rigorous and robust way, with peer review and analysis. As we move forward, we can hopefully put all of the hypotheses and studies together to continue to improve our understanding of this emerging disease process. Full transcript, well worth a read - hTTps://www.medscape.com/viewarticle/935165#vp_4
wan
11/8/2020
07:32
Nimbo...Analysts and indeed CareDX themselves, acknowledge the fact that new entrants are imminent. And I am quite sure that within those assumptions they include Renalytix and Verici.
wan
10/8/2020
19:13
Wan ref competition and care dx I sold on US open this morning taking a 4% loss, so no big deal. (having been 10% up after earnings)....earnings were good, I bet its comments on competition driving down the price. Renx nasdaq solid...chugging away.
nimbo1
10/8/2020
19:01
@buster - yes so am I am. I spoke to Halifax on friday. They noted the action took place and stated they were chasing the custodian for an update. Sounded more like they’ve not really followed up on the action? But at least they acknowledged it was for action.
2theduke
10/8/2020
11:12
yes waiting for HL but I sent them a message and they are contacting the registrar... will update if any news!
nimbo1
10/8/2020
09:33
Yes, not received mine via either HL or Barclays as of yet...
74tom
10/8/2020
09:25
Still waiting for the Verici shares to appear in my Halifax account. Anyone else in the same boat?
busterdog2
10/8/2020
08:59
Got notification of my Verici holding via Guinness AIM EIS - not heard from AJ Bell with other holding. yet.
toffeeman
10/8/2020
08:34
RNLX is up 27% since it’s IPO, if that’s classed as flatlining then I can’t wait to see a real rise! Interesting to see whether we do get analyst coverage & if so whether the Kantaro potential is flagged. And yes Wan, I agree both the future of Verici & $TECH links are very intriguing. Ever since I discovered the link between James McCulloch & TECH I’ve though that there is a real possibility they may look to acquire RENX in the future. Don’t think anything will happen for a while yet, but the Kantaro venture shows how close they are. I’m thinking something along the lines of the recent Livongo - Teledoc Health deal, just need RENX to get to $10b market cap first ;)
74tom
10/8/2020
08:00
From Seeking Alpha - Tuesday - August 11 Premarket: A big day is set in the IPO world with analysts free to post ratings on ALX Oncology (NASDAQ:ALXO), Pandion Therapeutics (NASDAQ:PAND), Berkeley Lights (NASDAQ:BLI) and Renalytix (NASDAQ:RNLX) following the quiet period expiration. ALXO and BCI have skyrocketed since their debuts and are likely to see some sell-side love, while flatlining PAND and RNLX are in greater need of strong defenses from analysts. So far in 2020, IPO quiet period expiration dates have been positive for share prices.
peterc1970
10/8/2020
07:56
An aspect I find quite intriguing is the fact the Exosomes diagnostics, which a Bio-Techne company, has (amongst many other things) a kidney transplant rejection urine test in development that is apparently relatively advanced. As another point of interest, Renalytix CEO James McCullough MBA, served as chief executive officer of Exosome Diagnostics Inc. from 2008 to 2014, which was acquired by Bio-Techne Corporation in 2018. Renalytix kidney transplant diagnostic portfolio, is now obviously contained within the Verici spin-off. Perhaps no connection, but clearly there is a strong partnership forming between Bio-Techne and Renalytix. And a suite of blood and urine tests might make for a compelling combination, and CareDX, listed in the US, has recently acknowledged competition is imminent.
wan
09/8/2020
14:20
Does anybody have a link to the RNLX retail roadshow presentation? Cant see to find it on the website any more - thanks :)
mysteronz
Chat Pages: 25  24  23  22  21  20  19  18  17  16  15  14  Older
ADVFN Advertorial
Your Recent History
LSE
RENX
Renalytix ..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20200812 15:05:37